The drug major Sun Pharma and AstraZeneca entered into a partnership for distribution of AstraZeneca’s diabetes medicine dapagliflozin in India.

Sun Pharma as a part of the agreement, will be selling AstraZeneca’s dapagliflozin which is a Type 2 diabetes medicine, under brand name Oxra.

AstraZeneca India markets dapagliflozin under the brand name Forxiga.

Sun Pharma said in a statement that both the companies would promote, market and distribute dapagliflozin in India under their respective brand names.

It further said that AstraZeneca will retain the intellectual property rights to dapagliflozin.

Read EquityPandit’s Nifty Pharma Out look for this week